{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:50:49Z","timestamp":1790668249186,"version":"4.1.0"},"reference-count":33,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"6","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precision Oncology"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p>Multidisciplinary molecular tumor boards (MTBs) interpret next-generation sequencing reports and help oncologists determine best therapeutic options; however, there is a paucity of data regarding their clinical utility. The purpose of this study was to determine if MTB-directed therapy improves progression-free survival (PFS) over immediately prior therapy in patients with advanced cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>This single-arm, prospective phase II clinical trial enrolled patients with advanced cancer with an actionable mutation who received MTB-recommended targeted therapy between January 1, 2017, and October 31, 2020. MTB-recommended both on-label (level 1 evidence) and off-label (evidence levels 2 and 3) therapies. Of the 93 enrolled patients, 43 were treated frontline and 50 received second-line or greater-line therapy. The primary outcome was the probability of patients treated with second-line or greater-line MTB-directed therapy who achieved a PFS ratio \u2265 1.3 (PFS on MTB-directed therapy divided by PFS on the patient's immediately prior therapy). Secondary outcomes included PFS for patients treated frontline and overall survival and adverse effects for the entire study population.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The most common disease sites were lung (35 of 93, 38%), gynecologic (17 of 93, 18%), GI (16 of 93, 17%), and head and neck (7 of 93, 8%). The Kaplan-Meier estimate of the probability of PFS ratio \u2265 1.3 was 0.59 (95% CI, 0.47 to 0.75) for patients treated with second-line or greater-line MTB-directed therapy. The median PFS was 449 (range 42-1,125) days for patients treated frontline. The median overall survival was 768 (range 22-1,240) days. There were four nontreatment-related deaths.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>When treated with MTB-directed therapy, most patients experienced improved PFS compared with immediately prior treatment. MTB-directed targeted therapy may be a strategy to improve outcomes for patients with advanced cancer.<\/jats:p><\/jats:sec>","DOI":"10.1200\/po.21.00524","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T19:58:22Z","timestamp":1663185502000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":21,"title":["Molecular Tumor Board\u2013Assisted Care in an Advanced Cancer Population: Results of a Phase II Clinical Trial"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9417-6642","authenticated-orcid":false,"given":"Rachel W.","family":"Miller","sequence":"first","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Markey Cancer Center, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8611-6324","authenticated-orcid":false,"given":"Megan L.","family":"Hutchcraft","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Markey Cancer Center, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi L.","family":"Weiss","sequence":"additional","affiliation":[{"name":"Shared Resource Facility, University of Kentucky Markey Cancer Center, Lexington, KY"},{"name":"Division of Cancer Biostatistics, Department of Internal Medicine, College of Medicine, University of Kentucky, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianrong","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Cancer Biostatistics, Department of Internal Medicine, College of Medicine, University of Kentucky, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Wang","sequence":"additional","affiliation":[{"name":"Shared Resource Facility, University of Kentucky Markey Cancer Center, Lexington, KY"},{"name":"Division of Cancer Biostatistics, Department of Internal Medicine, College of Medicine, University of Kentucky, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinpeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Shared Resource Facility, University of Kentucky Markey Cancer Center, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rani","family":"Jayswal","sequence":"additional","affiliation":[{"name":"Shared Resource Facility, University of Kentucky Markey Cancer Center, Lexington, KY"},{"name":"Division of Cancer Biostatistics, Department of Internal Medicine, College of Medicine, University of Kentucky, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikayla","family":"Buchanan","sequence":"additional","affiliation":[{"name":"Division of Precision Medicine, University of Kentucky Markey Cancer Center, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Anderson","sequence":"additional","affiliation":[{"name":"Division of Precision Medicine, University of Kentucky Markey Cancer Center, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5119-2474","authenticated-orcid":false,"given":"Derek B.","family":"Allison","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Kentucky, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1892-491X","authenticated-orcid":false,"given":"Riham H.","family":"El Khouli","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Kentucky, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reema A.","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, University of Kentucky Markey Cancer Center, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5583-0093","authenticated-orcid":false,"given":"John L.","family":"Villano","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, University of Kentucky Markey Cancer Center, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6542-9551","authenticated-orcid":false,"given":"Susanne M.","family":"Arnold","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, University of Kentucky Markey Cancer Center, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8575-4546","authenticated-orcid":false,"given":"Jill M.","family":"Kolesar","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Markey Cancer Center, Lexington, KY"},{"name":"Division of Precision Medicine, University of Kentucky Markey Cancer Center, Lexington, KY"},{"name":"Department of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100487"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-018-0813-2"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.2129"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv253"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.4298"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0163"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1111\/1467-9566.12970"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1200\/PO.16.00022"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp160211"},{"key":"b10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00169","volume":"2","author":"Freedman AN","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00495"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18613-3"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00210"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0386"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.5983"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.7150\/jca.3.7"},{"key":"b19","first-page":"181","volume":"5","author":"Lichtman SM","year":"2007","journal-title":"Clin Adv Hematol Oncol"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1653"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3123"},{"key":"b22","doi-asserted-by":"publisher","DOI":"10.1002\/pst.1916"},{"key":"b23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03010"},{"key":"b24","first-page":"100074","volume":"4","author":"Patel RA","year":"2021","journal-title":"Curr Probl Cancer Case Rep"},{"key":"b25","volume-title":"FDA Approves Pembrolizumab for Adults and Children With TMB-H Solid Tumors","author":"United States Food and Drug Administration","year":"2020"},{"key":"b26","doi-asserted-by":"publisher","DOI":"10.31525\/fda1-ucm560040.htm"},{"key":"b27","volume-title":"FDA Approves Niraparib for HRD-Positive Advanced Ovarian Cancer","author":"United States Food and Drug Administration","year":"2019"},{"key":"b28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1761"},{"key":"b29","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1799"},{"key":"b30","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10606"},{"key":"b31","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Non-small Cell Lung Cancer. Version 7.2021","author":"Ettinger DS","year":"2021"},{"key":"b32","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00008"},{"key":"b33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.102624"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO.21.00524","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T21:50:22Z","timestamp":1727992222000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO.21.00524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1200\/PO.21.00524"],"URL":"https:\/\/doi.org\/10.1200\/po.21.00524","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"2021-11-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2100524"}}